Labcorp Holdings Inc. (BMV:LH)
Mexico · Delayed Price · Currency is MXN 4,905.73
+26.44 (0.54%)
At close: Jun 11, 2025
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2013 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2013 - 2019 |
Diagnostics (Dx) | 10.14B | Log In | Log In | Log In | Log In | Upgrade |
Diagnostics (Dx) Growth | 8.22% | Log In | Log In | Log In | Log In | Upgrade |
Drug Development | - | Log In | Log In | Log In | Log In | Upgrade |
Drug Development Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other | -58.00M | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | 40.28% | Log In | Log In | Log In | Log In | Upgrade |
Biopharma Laboratory Services (BLS) | 2.92B | Log In | Log In | Log In | Log In | Upgrade |
Biopharma Laboratory Services (BLS) Growth | 3.87% | Log In | Log In | Log In | Log In | Upgrade |
Other | -58.00M | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | 40.28% | Log In | Log In | Log In | Log In | Upgrade |
EBIT by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2013 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2013 - 2019 |
Other | -927.20M | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | 5.88% | Log In | Log In | Log In | Log In | Upgrade |
Diagnostics (Dx) Operating Earnings | 1.61B | Log In | Log In | Log In | Log In | Upgrade |
Diagnostics (Dx) Operating Earnings Growth | 3.07% | Log In | Log In | Log In | Log In | Upgrade |
Drug Development Operating Earnings | - | Log In | Log In | Log In | Log In | Upgrade |
Drug Development Operating Earnings Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other | -927.20M | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | 5.88% | Log In | Log In | Log In | Log In | Upgrade |
Biopharma Laboratory Services (BLS) Operating Earnings | 458.90M | Log In | Log In | Log In | Log In | Upgrade |
Biopharma Laboratory Services (BLS) Operating Earnings Growth | 10.30% | Log In | Log In | Log In | Log In | Upgrade |
Other
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2013 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2013 - 2019 |
Organic Revenue Growth | 3.90% | Log In | Log In | Log In | Log In | Upgrade |
North America % Total Revenue | 87.00 | Log In | Log In | Log In | Log In | Upgrade |
North America % Total Revenue Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Europe % Total Revenue | 9.00 | Log In | Log In | Log In | Log In | Upgrade |
Europe % Total Revenue Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other Geography % Total Revenue | 4.00 | Log In | Log In | Log In | Log In | Upgrade |
Other Geography % Total Revenue Growth | - | Log In | Log In | Log In | Log In | Upgrade |